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Abstract
Background: Chronic migraine affects up to 2 % of the general population and has a substantial impact on sufferers.
Occipital nerve stimulation has been investigated as a potentially effective treatment for refractory chronic
migraine. Results from randomised controlled trials and open label studies have been inconclusive with little
long-term data available.
Methods: The long-term efficacy, functional outcome and safety of occipital nerve stimulation was evaluated in
an uncontrolled, open-label, prospective study of 53 intractable chronic migraine patients.
Results: Fifty-three patients were implanted in a single centre between 2007 and 2013. Patients had a mean
age of 47.75 years (range 26–70), had suffered chronic migraine for around 12 years and had failed a mean of 9
(range 4–19) preventative treatments prior to implant. Eighteen patients had other chronic headache phenotypes in
addition to chronic migraine. After a median follow-up of 42.00 months (range 6–97) monthly moderate-to-severe
headache days (i.e. days on which pain was more than 4 on the verbal rating score and lasted at least 4 h)
reduced by 8.51 days (p < 0.001) in the whole cohort, 5.80 days (p < 0.01) in those with chronic migraine alone
and 12.16 days (p < 0.001) in those with multiple phenotypes including chronic migraine. Response rate of the
whole group (defined as a >30 % reduction in monthly moderate-to-severe headache days) was observed in
45.3 % of the whole cohort, 34.3 % of those with chronic migraine alone and 66.7 % in those with multiple
headache types. Mean subjective patient estimate of improvement was 31.7 %. Significant reductions were also
seen in outcome measures such as pain intensity (1.34 points, p < 0.001), all monthly headache days (5.66 days,
p < 0.001) and pain duration (4.54 h, p < 0.001). Responders showed substantial reductions in headache-related
disability, affect scores and quality of life measures. Adverse event rates were favourable with no episodes of
lead migration and only one minor infection reported.
Conclusions: Occipital nerve stimulation may be a safe and efficacious treatment for highly intractable chronic
migraine patients even after relatively prolonged follow up of a median of over 3 years.
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Background
Chronic migraine (CM) is a highly disabling primary
headache disorder affecting approximately 2 % of the
general population [13, 27]. Chronic migraine is diag-
nosed when a patient has headaches on at least 15 days
per month, of which at least 8 days meet diagnostic cri-
teria for migraine [13]. Compared to episodic migraine,
CM sufferers report higher levels of headache related
disability and comorbid psychiatric disorders, reduced
rates of productivity at work or school and impaired
health-related quality of life [2, 3, 15, 23]. The annual
direct cost of chronic migraine is estimated to be
around €1800 in Europe and between $3500–$4150 in
the United States [7, 25]. Besides the costs of medical
treatment the associated indirect and socioeconomic
costs are huge with one recent web-based study report-
ing total annual costs of over $8000 amongst CM
patients [4, 24].
Treatment for CM is based on prophylactic medica-
tion aimed at reducing the frequency and severity of
migraine headaches. Despite best medical practice, it
is estimated that around 5 % of CM patients seen in
headache clinics will prove refractory to treatment
[31]. The definition of refractory chronic migraine is
not yet concrete, although European Headache Federation
guidelines propose that patients should meet diagnostic
criteria for CM, have failed adequate trials of at least three
preventive drugs, alone or in combination (from beta-
blockers, anticonvulsants, tricyclic antidepressants, flu-
narizine or candesartan, and OnabotulinumtoxinA),
and have received multidisciplinary input for any psy-
chiatric co-morbidities [21]. For this group of patients,
occipital nerve stimulation (ONS) has been carried
out with some promising results in both open-label
and controlled-trial evidence. However, results of the
placebo-controlled trials (all with follow-up periods of
just 3-months) have been interpreted with caution due
to contradictory outcomes and high adverse event
rates. The ONSTIM (occipital nerve stimulation for
the treatment of intractable chronic migraine head-
ache) feasibility trial quoted a responder rate of 39 %
in the active vs. 6 % in the sham group, yet the PRISM
(precision implantable stimulator for migraine) study
conducted soon after failed to show any significant dif-
ference between active and sham stimulation [17, 30]. The
largest sham-controlled study of ONS in CM, consisting
of 157 patients undergoing ONS for 3 months also
failed to show a significant difference in its primary
end-point of a 50 % reduction in pain intensity between
sham and active treatment. However, when this study
examined a 30 % reduction in end-point, a level repre-
senting a “much improved” state in chronic pain re-
search, a significant difference between groups was
observed [11, 34]. Open-label data has been more
positive with response rates of around 56 % although
follow-up periods have been relatively short [18].
With sparse data on follow-up past 12 months of
ONS implant, there is a need for studies examining the
sustained effects of treatment. This uncontrolled, open-
label prospective observational study reports on the
long-term outcomes of a single-center cohort of 53 pa-
tients with CM undergoing ONS.
Methods
Patients
Patients with medically intractable chronic migraine
seen in the headache clinic at the National Hospital for
Neurology and Neurosurgery, Queen Square, London,
UK were offered ONS. Patients were reviewed and oper-
ated on by a single multidisciplinary headache team and
were implanted over a 6-year period from March 2007
to December 2013. All patients fulfilled the International
Classification of Headache Disorders (ICHD) 2nd edition
and revised ICHD-3beta diagnostic criteria for CM and
also proposed criteria for intractable chronic migraine
[12, 14, 21], although, given the time period of the study
not all patients had received OnabotulinumtoxinA as
recommended in the recent European Headache Feder-
ation guidelines due to the fact that it was not approved
for use in the UK National Health Service until 2012
[21, 26]. Under the supervision of our institution’s Clin-
ical Effectiveness Supervisory Committee (CESG) with
arrangements for clinical governance, consent and audit,
we offered ONS to patients with medically intractable
CM. The procedure was provided on the basis of a
“humanitarian intervention”. In addition, ethics board
approval for data collection and publication was granted
by Northwick Park Hospital Research Ethics Committee,
Hampstead, London, UK.
Surgical procedure
Bilateral ONS electrodes, leads and an implantable pulse
generator (IPG) were implanted in all patients (Table 1).
Systems from both Medtronic (n = 47) and St Jude Med-
ical (n = 6) were utilized with octad electrodes used in 51
patients and quad electrodes in two. The patient was
placed into the lateral position and a midline posterior
cervical incision made. Initially, the insertion point of
the electrodes was the spinous process of C1, passing su-
perior and laterally, using a curved Tuohy needle and an
image intensifier to aid positioning. This method evolved
over time so that implantation level was aimed at the
greater occipital nerve as it emerged superior to the nu-
chal line. In this amended technique, the electrode was
passed using a blunt plastic tube to limit the risks of the
electrode tip being tunneled too close to the skin. The
evolution of surgical technique occurred in response to
adverse events such as recruitment of neck muscles
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during stimulation or erosion of the electrode tip
through the scalp. Given that both techniques target the
same nerve it is felt unlikely that the implant technique
would directly account for changes in efficacy. Elec-
trodes were looped and anchored to cervical fascia and
then tunneled to a lateral cervical or infraclavicular skin
crease intermediate incision. An infraclavicular or ab-
dominal incision was made (according to patient prefer-
ence) and a pocket formed into which the IPG was placed.
Electrodes were tunneled to the intermediate incision
site where a pair of extension leads were connected.
Silicone sheaths were used to protect lead connections.
Topical gentamicin was introduced around the pocket
prior to closure. Our unit did not employ trial stimula-
tion as it was felt that the current evidence to support
its use is outweighed by the risks of extra surgical
procedures.
At initial programming, frequency was set at 60Hz
with a pulse width of 240 μs. Polarity of the electrodes
was adjusted during follow up visits to ensure comfort-
able bilateral paresthesia in the bilateral occipital region.
Patients were provided with remote controls allowing
them to adjust their stimulation amplitude but were
asked to use continuous stimulation where possible.
Stimulation settings and changes were recorded at each
visit. Medications were changed as needed at the discre-
tion of the headache specialist.
Data collection
Data were collected prospectively and entered onto a clin-
ical database (Microsoft Excel, Microsoft Corporation,
Redmond, WA, USA). Data including demographics,
diagnosis, daily pain severity and duration, previous
and current treatments, and adverse events were re-
corded. Patients were reviewed in clinic every 3 months
for the first year and then every 6 to 12 months there-
after. Patients prospectively completed headache diaries
recording pain severity on a verbal rating scale (VRS; 0 =
no pain to 10 = extreme pain) and daily pain duration (in
hours) for 1 month prior to implant and 2 weeks prior to
each follow-up visit. This 2-week data was used to calcu-
late the mean monthly moderate-to-severe headache days
(days on which pain of VRS ≥ 4 lasting at least 4 h), mean
monthly headache days (days on which any pain was re-
corded), mean daily pain severity and mean daily hours
of pain over these periods of time. Where multiple
headache types were present, patients were asked to
differentiate between these and separate diaries com-
pleted for each to allow the outcome of each phenotype
to be established (examples of the headache diaries
used to record chronic migraine are included in the
Additional file 1: Figure S1).
Migraine Disability Assessment Scores (MIDAS) and
Headache Impact Test 6 Scores (HIT-6), both validated
for their use in migraine, were recorded pre- and post-
ONS to monitor headache related disability. Euro-QoL
(Euro-QoL 5D index [EQ-5D] and Euro-QoL visual
analogue score [EQ-VAS]), Short Form 36 Question-
naires (SF36), Beck Depression Inventory II (BDI-II),
Hospital Anxiety (HAD-A) and Hospital Depression
(HAD-D) Scores were used to monitor quality of life
and mental state pre- and post-implant. Patients were
asked to provide a subjective global estimate of im-
provement in their migraine headaches from 0 to 100 %
at follow-up.
Details of any adverse events were recorded through-
out follow-up as they occurred. Events were categorized
as “hardware related” if they involved problems with the
device components, “biological” if they were reactions to
the device or surgical procedure and “stimulation re-
lated” if they involved stimulation issues [34].
The primary outcome measure was the improvement
in mean monthly moderate-to-severe headache days at
final follow up compared to the baseline. A responder
was defined as a patient who had a 30 % or more re-
duction in mean monthly moderate-to-severe headache
days. Secondary outcome measures included changes in
monthly moderate-to-severe headache days at each
time point, mean monthly headache days, mean daily
pain intensity, mean daily pain duration, headache-
related disability scores, affective measures and quality
of life scores. Adverse events were also examined.
Statistics
All statistical analyses were conducted using IBM SPSS
Statistics version 22 (IBM Corp. Int.). A last observation
carried forward technique was used in the case of




Medtronic 47 (88.6 %)
St Jude 6 (11.3 %)
IPG
Standard 6 (11.3 %)
Rechargeable 24 (45.3 %)
Standard changed to rechargeable 23 (43.4 %)
Electrodes
Quad 2 (3.8 %)
Octad 51 (96.2 %)
IPG Site
Abdomen 21 (39.36 %)
Infraclavicular 23 (43.4 %)
Abdomen moved to infraclavicular 9 (17.0 %)
IPG implantable pulse generator, ONS occipital nerve stimulator
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missing data. Descriptive statistics were summarized as
appropriate. Data is presented as mean ± standard devi-
ation (SD), range and frequencies. Paired and independ-
ent t-tests were used to compare treatment effect as
appropriate. All statistical tests were two-sided with a




Fifty-three patients (37 female) with intractable CM
underwent bilateral ONS insertion between March 2007
and December 2013 (Table 2). The mean age at implant
was 47.75 years (±11.48). Patients had suffered chronic
migraine for a mean of 11.77 years (±10.90). The cohort
had failed a mean of 9.36 (±2.61) preventative medica-
tions prior to implant (Table 3). Only 22.6 % of patients
had reported a previous response to greater occipital
nerve block (response defined as a more than 50 % re-
duction in headache severity or frequency lasting at least
2 weeks).
Eighteen patients (35.3 %) reported other headache
phenotypes in addition to chronic migraine: ten with
chronic cluster headache; five with short lasting unilat-
eral neuralgiform headache attacks; two with chronic
cluster headache and short lasting unilateral neuralgi-
form headache attacks; and, one with short lasting uni-
lateral neuralgiform headache attacks and hemicrania
continua (Table 2). All kept separate diaries for each
phenotype throughout the follow-up period (Additional
file 1: Figure S1).
Twenty patients (37.7 %) were overusing acute medi-
cations at time of implant (as defined by ICHD-3b cri-
teria). All of those with CM alone had previously
undergone a medication withdrawal as part of their
routine clinical treatment and failed to report any sig-
nificant improvement in their headaches, thereby ex-
cluding medication overuse headache.
Whole cohort
Median follow-up time was 42.00 months with a range
of 6–97 months. At follow-up, five patients had had
their ONS devices removed due to lack of efficacy and a
further three had the device switched off for the same
reasons. There was no significant difference in the
follow-up time of responders and non-responders (p =
0.619). The primary outcome of a 30 % or more reduc-
tion in moderate-to-severe headache days was observed
in 45.3 % (n = 24) at final follow-up. Monthly moderate-
to-severe headache days fell by 8.51 days (95%CI 5.63,
11.38; p < 0.001) a reduction of 37.1 %. Figure 1a shows
the change in moderate-to-severe headache days over
the follow-up period. A reduction of 50 % or more in
monthly moderate-to-severe headache days was seen in
Table 2 Demographic data
Age
Mean (SD) 47.75 years (±11.48)
Range 26–70 years
Sex
Male 16 (30.2 %)
Female 37 (69.8 %)
Laterality
Unilateral 33 (62.3 %)
Bilateral 20 (37.7 %)
Aura 28 (52.9 %)
Visual 22 (41.5 %)
Sensory 15 (28.3 %)
Hemiplegic 6 (11.3 %)
Speech 5 (9.4 %)
Duration from onset of migraine
Mean (SD) 31.51 years (±14.52)
Range 5–58 years
Duration from onset of Chronic Migraine
Mean (SD) 11.77 years (±10.90)
Range 3–48 years
Co-existent headache types 18 (33.9 %)
Chronic cluster headache 10 (18.7 %)
SUNCT/SUNA 5 (9.4 %)
Chronic cluster headache + SUNCT/SUNA 2 (3.8 %)
SUNCT/SUNA + hemicrania continua 1 (1.9 %)
Number of headache types
1 35 (66.0 %)
2 15 (28.3 %)
3 3 (5.7 %)
Monthly days of acute medication
Mean (SD) 11.77 (±10.34)
Range 0–30
Medication overuse at implant 20 (37.7 %)
Mean number of preventatives prior to ONS
Mean (SD) 9.36 (±2.61)
Range 4–19
Prior response to GON block 12 (22.6 %)
Follow up since ONS implant
Median 42.00 months
Mean (SD) 46.79 months (±21.70)
Range 6–97 months
GON greater occipital nerve, ONS occipital nerve stimulation, SD standard
deviation, SUNA short lasting unilateral neuralgiform headache attacks with
autonomic features, SUNCT short lasting unilateral neuralgiform headache
attacks with conjunctival injection and tearing
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37.7 % (n = 20). Significant reductions were seen in mean
any-headache days (−5.66), mean daily pain duration
(−4.54 h) and mean daily pain intensity (−1.34 points on
VRS) (Table 4). Although a significant reduction of 3.94
points was recorded in HIT-6, the reduction in MIDAS
was not significant (−20.62). Affect scores, EQ5D and
SF-36 composite scores failed to show any improvement
across the cohort but the Euro-VAS did show significant
improvement (Table 5).
Clinical non-responders failed to show any improve-
ment in any-headache days, severity or duration, head-
ache related disability, quality of life or affect scores.
Responders showed significant improvements in HIT-6
(−7.75, p = 0.009), HAD-D (−2.98, p = 0.012), BDI-II
(−7.04 points, p = 0.012), Euro-VAS (42.93 points, p <
0.001) and both SF-36 Physical (4.59 points, p = 0.017)
and Mental Composite scores (5.12 points, p = 0.034).
In responders, significant improvements were also ob-
served in headache days (−11.50, p < 0.001), pain sever-
ity (−2.75 points, p < 0.001) and daily pain hours (−8.60,
p < 0.001).
Patient estimated improvement in their migraine at
final follow-up was 31.7 % (±33.12) and 23 (46 %) would
recommend the device to others. For responders, esti-
mated improvement was 40.0 % (±38.27) and in non-
responders 15.0 % (±24.54).
Responder rates of changes in pain intensity and com-
binations in headache frequency and severity are sum-
marized in Fig. 2.
Chronic migraine alone
In the 35 patients with CM alone, the median follow-up
time was 39.00 months. A 30 % or more reduction in
moderate-to-severe headache days was observed in
36.4 % (n = 12) at final follow-up. Monthly moderate-to-
severe headache days fell by 5.80 days (95%CI 2.76, 8.83;
p = 0.010) a reduction of 26.0 %. Figure 1b shows the
change in monthly moderate-to-severe headache days
over time. The average time to reach a 30 % improve-
ment (calculated using diary scores at each time point
available) was 7.05 months (±6.47). A reduction of at
least 50 % in moderate-to-severe headache days was seen
in 27.3 % (n = 9). Significant reductions were seen in
mean any-headache days (−3.11 days), mean daily pain
duration (−2.75 h) and mean daily pain score (−1.20
points on VRS) (Table 4). Although a reduction was seen
in MIDAS scores at final follow-up this was not signifi-
cant (−26.20 points). The HIT-6 score did show a signifi-
cant reduction, however (−3.65 points) (Table 5). Affect
scores did not show significant changes. Quality of life
scores showed significant improvement in SF36 Mental
composite scores (4.14 points) but not in EQ-5D, EQ-
VAS or SF-36 Physical composite scores (Table 5).
Multiple phenotypes including CM
In those 18 patients with multiple headache types includ-
ing CM, the median follow-up time was 45.00 months
(range 17–87). The 30 % response rate was 66.7 % (n = 12)
which is significantly greater than the response rate of
those with CM alone at final follow-up (p = 0.012). How-
ever, at no other time-point was a significant difference
seen between those with single vs. multiple headache
types (Fig. 1b). Monthly moderate-to-severe headache
days fell by 12.16 days (95 % CI 6.63, 17.69; p < 0.001) a re-
duction of 58.7 %. The average time to reach a 30 % im-
provement was 5.33 months (±2.74). A 50 % or more
reduction in moderate-to-severe headache days was seen
in 61.1 % (n = 11). Significant reductions were seen in
mean any-headache days (−10.61 days), mean daily pain
duration (−7.91 h) and daily pain intensity (−1.61 points
on VRS) (Table 4). Neither MIDAS nor HIT-6 showed
any significant change (Table 5). Affect scores, EQ5D, EQ-
VAS and SF-35 Mental composite scores failed to show
any improvement but SF-36 Physical composite showed
significant improvement at final follow-up.
In CM responders, 6/9 CCH, 3/4 short lasting unilat-
eral neuralgiform headache attacks and 1/1 hemicrania
continua responded to ONS (defined as a more than
50 % reduction in daily attack frequency for CCH and
short lasting unilateral neuralgiform headache attacks,









Beta-Blockers 42 (79.2 %) 30–320 140.80
Topiramate 49 (92.4 %) 25–400 170.65
Sodium
Valproate
47 (88.6 %) 300–2500 1047.50
Gabapentin 51 (96.2 %) 300–3600 2206.97
Pregabalin 32 (60.3 %) 50–600 384.16
Flunarizine 36 (67.9 %) 5–20 8.79
Pizotifen 45 (84.9 %) 1.5–4.5 2.39
Methysergide 44 (83.0 %) 1–12 6.10
Tricyclic
Antidepressant:
51 (96.2 %) – –
Amitriptyline 44 (83.0 %) 10–150 56.31
Dosulepin 28 (52.8 %) 25–225 101.73
NSAID 42 (79.2 %) – –
Acupuncture 3 (5.7 %) – –
Botox 7 (13.2 %) – –
IV DHE 45 (84.9 %) – –
GONB 53 (100 %) – –
Botox OnabotulinumtoxinA, DHE Dihydroergotamine, GONB greater occipital
nerve block, IV intravenous, NSAID non-steroidal anti-inflammatory drug
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35 35 35 34 33 31 19 35
Multiple
phenotypes
18 18 18 18 18 17 13 18
p value N/A 0.878 0.745 0.424 0.886 0.526 0.442 0.012*
b
a
Fig. 1 Changes in moderate-to-severe headache days following occipital nerve stimulation. a Improvement of moderate-to-severe headache days
of whole cohort over follow-up period. b Improvement in moderate-to-severe headache days of those with chronic migraine alone compared to
those with multiple phenotypes over follow-up period. Table provides number of subjects included at each time point
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and a more than 30 % reduction in moderate-to-severe
daily headache days for hemicrania continua). In CM
non-responders, 2/3 CCH and 4/5 short lasting unilat-
eral neuralgiform headache attacks responded to ONS.
Acute medication use
The mean number of days on which patients used any
acute medication fell by 2.43 days (p = 0.154). There was
no change in the proportion of patients overusing acute
medication pre- and post-treatment (37.7 v. 35.8 %) (p =
0.840). The proportion recording acute medication overuse
prior to implant did not differ in responders and non-
responders (55 v 27 %; p = 0.078).
Preventative medication use
Twenty-three patients were taking at least one preventa-
tive medication at implant. Following ONS, six patients
(26.1 %) had stopped all medications, four (17.4 %) had
reduced the dose of or stopped at least one medication,
eight (34.8 %) had had no change in their medication
doses and five (21.7 %) had increased the dose or num-
ber of medications taken.
Table 4 Summary of efficacy outcome measures of occipital nerve stimulation for chronic migraine
Outcome measure Prior to ONS Post-ONS Percentage change Mean change (95 % CI) p Value
Whole cohort (n = 53)
Headache daysa (±SD) 29.57 (±2.12) 23.91 (±10.04) 20.0 % (±32.91) 5.66 < 0.001*
Range 18–30 0–30 0–100 (3.07, 8.25)
Moderate-to-severe headache daysa (±SD) 26.51 (±6.48) 18.00 (±12.79) 37.1 % (±41.27) 8.51 < 0.001*
Range 5–30 0–30 0–100 (5.63, 11.38)
Average daily pain intensity VRS (±SD) 6.00 (±1.71) 4.66 (±2.59) 27.8 % (±32.87) 1.34 < 0.001*
Range (VRS) 3–9 0–10 0–100.0 (0.64, 2.03)
Average daily headache hours (±SD) 16.06 (±5.38) 11.52 (±7.12) 31.6 % (±37.12) 4.54 < 0.001*
Range (hours) 2–24 0–24 0–100 (2.62, 6.45)
Mean Patient estimated benefit (±SD) 31.7 % (±33.12)
Range 0–100
Chronic migraine alone (n = 35)
Headache daysa (±SD) 29.34 (±18–30) 26.23 (±8.26) 12.0 % (±26.29) 3.11 < 0.001*
Range 18–30 2–30 0–93 (0.79, 5.43)
Moderate-to-severe headache daysa (±SD) 26.83 (±6.74) 21.03 (±11.33) 26.0 %(±34.58) 5.80 0.010*
Range 5–30 0–30 0–100 (2.76, 8.83)
Average daily pain intensity VRS (±SD) 6.09 (±1.63) 4.89 (±2.34) 23.7 % (±28.40) 1.20 0.003*
Range (VRS) 3–9 0–9 0–100 (0.43, 1.96)
Average daily headache hours (±SD) 15.10 (±4.15) 12.44 (±6.18) 24.5 % (±34.24) 2.75 0.003*
Range (hours) 2.0–24.0 0–24.0 0–100 (0.99, 4.50)
Mean Patient estimated benefit (±SD) 30.0 % (±29.77)
Range 0–95
Multiple headache phenotypes (n = 18)
Headache daysa (±SD) 30.00 (±0.0) 19.39 (±11.80) 35.3 % (±39.37) 10.61 0.001
Range 30 0–30 0–100 (4.73, 16.48)
Moderate-to-severe headache daysa (±SD) 25.94 (±5.90) 13.78 (±13.97) 58.7 % (±45.48) 12.16 < 0.001
Range 10–30 0–30 0–100 (6.63, 17.69)
Average daily pain intensity VRS (±SD) 5.83 (±1.88) 4.22 (±3.04) 23.7 % (±28.40) 1.61 0.039
Range (VRS) 3–9 0–10 0–100 (0.09, 3.12)
Average daily headache hours (±SD) 17.72 (±6.96) 9.80 (±8.53) 45.4 % (±39.56) 7.91 0.001
Range (hours) 5.0–24.0 0.0–24.0 0–100 (3.62, 12.21)
Mean Patient estimated benefit (±SD) 35.2 % (±39.53)
Range 0–100
CI confidence interval, ONS occipital nerve stimulation, SD standard deviation, VRS verbal rating scale
*P value less than 0.05; atime period one month
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Table 5 Headache related disability, affect and quality of life scores following occipital nerve stimulation
Pre ONS (n = 53) Post ONS (n = 53) Mean Change in Score
(95 % CI)
p-value
Whole cohort (n = 53)
MIDAS 0.188
Mean (±SD) 154.91 (±84.03) 134.28 (±92.70) 20.62
Range 18–270 0–270 (−10.41, 51.65)
HIT-6 0.009*
Mean (±SD) 69.17 (±6.88) 65.23 (±9.27) 3.94
Range 52–98 36–89 (1.04, 6.84)
HAD-A 0.618
Mean (±SD) 10.34 (±4.46) 9.96 (±4.86) 0.377
Range 2–21 0–19 (−1.13, 1.88)
HAD-D 0.127
Mean (±SD) 11.36 (±4.23) 10.26 (±5.40) 1.09
Range 1–20 0–20 (−0.32, 2.51)
BDI-II 0.132
Mean (±SD) 26.11 (±11.07) 23.13 (±13.59) 2.98
Range 2–46 0–59 (−0.93, 6.89)
SF-36 Physical Composite 0.054
Mean (±SD) 27.12 (±8.16) 29.41 (±11.43) −2.29
Range 11.1–15.9 12.1–55.7 (−4.62–0.04)
SF-36 Mental Composite 0.076
Mean (±SD) 34.72 (±11.54) 37.97 (±13.25) −3.25
Range 19.6–62.5 9.8–61.2 (−6.84–0.35)
EQ5D
Mean (±SD) 0.66 (±0.11) 0.64 (±0.15) 0.02 0.317
Range 0.26–0.83 0.25–1.0 (−0.16–0.05)
EQ-VAS
Mean (±SD) 40.51 (±21.09) 49.78 (±25.00) 9.27 0.009*
Range 0–90 5–95 (−16.09– −2.43)
Chronic migraine alone (n = 35)
MIDAS
Mean (±SD) 162.17 (±86.50) 135.97 (±91.33) 26.20 0.194
Range 18–270 0–270 (−13.95,66.35)
HIT-6
Mean (±SD) 69.91 (±6.72) 66.26 (±8.14) 3.65 0.038*
Range 61–98 36–78 (0.21, 7.10)
HAD-A
Mean (±SD) 10.69 (±4.33) 10.83 (±4.42) −0.14 0.864
Range 2–21 2–18 (−1.82, 7.10)
HAD-D
Mean (±SD) 11.91 (±4.09) 11.34 (±5.01) 0.57 0.396
Range 3–20 1–19 (−0.78, 1.92)
BDI-II
Mean (±SD) 27.09 (±11.22) 24.37 (±13.03) 2.71 0.199
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Table 5 Headache related disability, affect and quality of life scores following occipital nerve stimulation (Continued)
Range 2–45 0–48 (−1.49, 6.92)
SF-36 Physical Composite
Mean (±SD) 27.71 (±8.11) 27.69 (±10.58) 0.02 0.986
Range 11.10–45.90 12.10–55.0 (−2.6, 2.73)
SF-36 Mental Composite
Mean (±SD) 32.71 (±11.20) 36.86 (±12.72) −4.14 0.039*
Range 19.60–62.50 9.80–61.20 (−80.7, −0.22)
EQ5D
Mean (±SD) 0.56 (±0.12) 0.62 (±0.15) 0.03 0.105
Range 0.26–0.83 0.25–0.83 (−0.01, 0.07)
EQ-VAS
Mean (±SD) 42.43 (±22.44) 48.64 (±22.87) −6.21 0.057
Range 10–90 10–90 (−12.63, 0.20)
Multiple phenotypes (n = 18)
MIDAS
Mean (±SD) 140.78 (±79.46) 131.00 (±97.89) 9.77 0.701
Range 24–270 0 + 270 (−42.96, 62.52)
HIT-6
Mean (±SD) 67.72 (±7.16) 63.22 (±11.14) 4.50 0.122
Range 52–78 42–89 (−1.33, 10.33)
HAD-A
Mean (±SD) 9.67 (±4.75) 8.28 (±5.36) 1.38 0.377
Range 3–18 0–19 (−1.84, 4.62)
HAD-D
Mean (±SD) 10.44 (±4.69) 8.17 (±5.63) 2.27 0.178
Range 1–19 0–20 (−1.14, 5.69)
BDI-II
Mean (±SD) 24.22 (±10.85) 20.72 (±14.68) 3.50 0.415
Range 6–46 0–59 (−5.33, 12.33)
SF-36 Physical Composite
Mean (±SD) 26.85 (±7.59) 36.36 (±12.55) −5.91 0.010*
Range 13.70–42.50 12.70–55.70 (−10.23, −1.58)
SF-36 Mental Composite
Mean (±SD) 36.36 (±11.24) 40.13 (±14.35) −3.77 0.329
Range 20.10–59.40 15.30–59.50 (−11.68, 4.14)
EQ5D
Mean (±SD) 0.65 (±0.85) 0.67 (±0.13) −0.14 0.619
Range 0.54–0.83 0.41–1.00 (−0.77, 0.04)
EQ-VAS
Mean (±SD) 37.35 (±18.88) 51.65 (±28.81) −14.29 0.069
Range 10–70 5–95 (−29.85, 1.26)
BDI-II, Becks Depression Inventory; CI, confidence interval; EQ-VAS, Euro-QoL visual analogue score; EQ5D, Euro-QoL 5D Index; HAD-A, Hospital Anxiety and Depression
scores-anxiety specific; HAD-D, Hospital Anxiety and Depression scores – depression specific; HIT-6, Headache Impact Test; MIDAS, Migraine Disability Assessment Scale;
ONS, occipital nerve stimulation; SD (Standard deviation); SF-36, Short Form 36
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Time to effect and recurrence of attacks
The median time of the whole cohort to reach a 30 %
improvement in moderate-to-severe headache days was
5.50 months (range 1–24 months). In responders, the
median time was 4.00 months. Although a significant
difference was seen in moderate-to-severe headache days
between baseline and three months in responders
(7.70 days, p < 0.001), no such change was seen between
months 3 and 6 (p = 0.705), 3 and 9 (p = 0.498) or 3 and
12 months (p = 0.918).
Twenty-one subjects had their ONS turned off for a
period of time – 13 due to battery depletion, six due to
lack of efficacy and two due to ONS technical issues. In
15 patients, migraine pain worsened when the ONS was
off. The mean time to pain worsening was 2.47 (range
1–6 months). There was no difference in 30 % response
rate of those who had their ONS switched off temporar-
ily at any point (p = 0.777).
Stimulation settings
Mean stimulation amplitude was 1.46 V (range 0.29–3.95),
pulse width 449.90 μs (range 370–570) and frequency
72.13Hz (range 50–140).
Adverse events
Adverse events were categorized as “hardware related” if
they involved problems with the device components,
“biological” if there were reactions to the device or surgi-
cal procedure and “stimulation related” if they involved
stimulation issues (Table 6). In total, 54 events were re-
corded in 26 patients. Twenty-two hardware issues were
recorded including ten system revisions (18.9 %), five ex-
plantations secondary to lack of efficacy (9.4 %) and four
battery depletions in under 1 year (7.5 %). Three elec-
trode erosions (5.7 %) were seen, none associated with
infection, which all required surgical intervention. No
episodes of lead migration or fracture were recorded.
One episode of infection of a wound site was observed
that received medical management only.
Discussion
Weiner and Reed were the first to report the potential
use of ONS for intractable occipital neuralgia [36]. Sub-
sequent review and imaging of the patients by headache
specialists, however, suggested many of these patients
actually had CM [22]. There have now been three
placebo-controlled studies on ONS in CM and although
Fig. 2 Responder rates of all chronic migraine patients to prolonged occipital nerve stimulation treatment by outcome measure. Various outcome
measures have been used across the occipital nerve stimulation literature to measure response in chronic migraine. The response rate of the
cohort is shown for each of these outcome measures – headache days, pain intensity and a combination of headache days and/or pain
intensity. VRS verbal rating scale
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their results have been somewhat contradictory recent
meta-analysis suggests an overall positive effect of treat-
ment [17, 30, 34, 37]. The PRISM (Precision Implantable
Stimulator for Migraine) study conducted by Lipton et
al., only available in abstract form, failed to show a sig-
nificant difference in the reduction of migraine days/
month between the active and sham groups after
12 weeks (−5.5 vs. 3.9 days/month, p = 0.29) [17]. Saper
et al. published results of the ONSTIM (Occipital nerve
stimulation for the treatment of intractable chronic mi-
graine headache) trial in 2010 [30]. Of the 77 patients
included, all subjects had failed to respond to at least
two different classes of medication and had reported
positive response to greater occipital nerve block. Vari-
ous outcome measures including reduction in headache
days, pain intensity and pain duration were numerically
superior in the treatment group. A responder was de-
fined in this study as a subject reporting a more than
50 % reduction in monthly headache days or a more
than three-point reduction in average pain intensity.
Three-month responder rates were 39 % for the active
group, 6 % for the sham-control group and 0 % for the
medical management group. The percentage reduction
in severe headache days a month was 24.4 % (±43.6) for
the active group and 10.3 % (±34.0) for the sham group,
corresponding to a reduction of 5.1 days (±8.7) a month
in the active group and 2.2 (±6.4) in the sham group.
The largest randomized sham-controlled study on ONS
in CM was conducted on 157 subjects by Silberstein et
al. [34]. This group failed to find a significant difference
in the primary outcome measure (those achieving a
more than 50 % reduction in average pain intensity at
12 weeks) between active (17.1 %) and sham (13.1 %)
stimulation groups. However, a number of secondary
outcomes did suggest that ONS had a benefit including
the numbers achieving a 30 % reduction in pain severity
and a 30 % reduction in headache frequency. Long-
term open-label follow-up of this cohort for a total of
12 months revealed that there was a significant reduc-
tion in the number of headache days (defined as days
with more than 4 h of moderate-to-severe pain) of
6.7 days (±8.4) [10]. The percentage reporting a more
than 50 % reduction in headache days and/or pain in-
tensity was 47.8 %. Pooled results from these three tri-
als show that ONS is associated with a mean reduction
of 2.59 moderate-to-severe headache days a month
(95 % CI 0.91, 4.27) after 3 months treatment compared
with sham control [8].
Several open-label series have been published sug-
gesting efficacy of ONS in CM, however, many of these
have been of small numbers with restricted follow-up.
Two centers analyzed their long-term data in retro-
spective reviews. Brewer et al. reported 12 CM patients
with average follow-up of 34 months (range 1–70
Table 6 Summary of adverse events of prolonged follow-up of ONS for chronic migraine
Adverse event Surgical intervention Medical management Total events
Hardware related Lead migration 0 0 0
Lead fracture 0 0 0
Electrode erosion 3 (5.7 %) 0 3 (5.7 %)
ONS system revision 10 (18.9 %) 0 10 (18.9 %)
Change to rechargeable system 9 (17.0 %)
Secondary to lead tethering 1 (1.9 %)
Explantation
(Due to efficacy)
5 (9.4 %) 0 5 (9.4 %)
Battery depletion:
(Failure in under one year)
4 (7.5 %) 0 4 (7.5 %)
Total hardware related events 22
Biological Infection 0 1 (1.9 %) 1 (1.9 %)
Pain over IPG/lead/wound sites 1 (1.9 %) 5 (9.4 %) 6 (11.3 %)
Neck stiffness 0 8 (15.1 %) 8 (15.1 %)
Allergy to surgical material 0 1 (1.9 %) 1 (1.9 %)
Wound site complication 0 2 (3.8 %) 2 (3.8 %)
Total biological related events 18
Stimulation associated Undesirable changes in stimulation 0 14 (26.4 %) 14 (26.4 %)
Total stimulator associated events 14
Total 54 events (involving 26 patients)
IPG implantable pulse generator, IV intravenous, ONS Occipital nerve stimulator
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months) and Palmisani et al. reported 19 CM patients
with average follow-up of 10 years (range 1–19 years)
[5, 29]. Outcome in both was based on the patients
subjective reporting via a telephone interview. In the
Brewer series, five patients (41.6 %) reported a more
than 50 % overall benefit whereas nine (47.3 %) of the
Palmisani series reported a more than 50 % reduction
in pain intensity and/or frequency.
Our uncontrolled, open-label, prospective observa-
tional study showed that in highly refractory CM pa-
tients with prolonged follow-up, ONS resulted in a
significant reduction of moderate-to-severe headache
days a month (8.51 days). In total, 45.3 % of patients
showed a more than 30 % reduction of monthly
moderate-to-severe headache days following treatment.
Five patients were completely pain free and had been
for prolonged periods. Significant improvements were
also seen in pain intensity, daily pain duration and
headache related disability. Although our response rate
is below that of the open label series quoted above, our
outcome measure is objective and from prospectively
completed headache diaries and is thus a more robust
measure. The use of a 30 % improvement in outcome
measure is accepted in the chronic pain literature as
representing a “much improved” clinical state and has
been accepted by both the International Headache So-
ciety clinical trials subcommittee as being a realistic
and clinically relevant improvement in those with
chronic migraine [10, 11, 33]. With this is mind and
with such a complex group of patients present in this
cohort, we feel that a 30 % improvement level is
justified.
The primary outcome measure of moderate-to-severe
headache days was chosen in accordance with the 2008
guidelines for controlled trials of prophylactic treatment
of chronic migraine in adults produced by the Clinical
Trials Subcommittee of the International Headache So-
ciety [33]. However, a wide variety of headache outcome
measures (e.g. “headache days”, pain intensity) have been
used in previous case series of ONS for CM and so dir-
ect comparison between studies can be somewhat diffi-
cult. With this in mind, there is an obvious need for a
consensus on the most appropriate outcome measures
for ONS efficacy. Our group is also more complicated
than those in the previous series with many suffering
multiple chronic headache conditions, reporting a higher
number of failed past medications and with 94.3 % of
them recording background or interictal pain. In such
an intractable group of patients, a continued response in
over one-third of patients after such prolonged follow-
up should be viewed with cautious optimism.
The rates of serious adverse event in our series was
below that of previous reported groups. In the random-
ized trials, concerns were raised over the high rates of
lead migration and infection. The ONSTIM trial quoted
rates of lead migration at 24 % and infection in at least
18 % of patients, whilst the Silberstein study reported
rates of 19 and 7 %, respectively. Our group had no epi-
sodes of lead migration and only a single episode of mild
wound site infection treated with oral antibiotics. Our
implants were conducted by a single highly skilled surgi-
cal team and our results mirror those found by Sharan
et al. in describing high levels of implanter experience
being associated with significantly lower levels of com-
plications [32]. Recent guidelines recommending that
ONS should only be carried out in a limited number of
highly specialized centers should lead to improvements
in adverse event rates and a reduction in the current dis-
crepancy between centres.
Our group do not conduct trial-periods of stimula-
tion as is carried out in a number of other centres. The
intention of such trials is that they will positively select
those most likely to respond to long-term ONS treat-
ment and they have in-fact been used as inclusion cri-
teria for a number of controlled trials. However, it is
clear that a positive trial does not guarantee longer-
term success. In the study by Silberstein et al., despite
all subjects having a positive trial period, the study still
failed to reach its primary endpoint [34]. Other open-
label series support the view that trial stimulation does
not predict success. Palmisani et al. had a trial success
rate of 88 % but removed 7/23 systems implanted due
to lack of efficacy and Brewer et al. reported high trial
success rates (89 %) but a long-term benefit in only
42 % CM patients [5, 29]. A study using longer trial-
periods of one month has also failed to show an associ-
ation between trial response and ONS outcome [28].
Our data suggests that there is a delay in patients
reporting clinical effect of ONS which may be up to 6
months in responders. This may explain why trial
stimulation does not predict success and suggests that
the early response reported by some groups may be due
to a placebo effect. The hypothesis that the neuromo-
dulatory effects of ONS are due to slow, plastic changes
within the pain-structures of the brain is supported by
our data on time to clinical effect and observation of
gradual return of pain when ONS is stopped. This hy-
pothesis of plastic-change is in direct conflict to the
rapid action seen in trial stimulation. Given that re-
sponse rates in those groups using trial stimulation are
similar to our patients who do not undergo such trials,
we do not feel that the current evidence supports the
use of trial stimulation and the additional surgical risks
this entails. This remains a controversial area and we
support further investigation into the true predictive
value of trial stimulation in ONS.
This is the first study on ONS in CM to include a sig-
nificant proportion of patients with multiple headache
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phenotypes. Nearly a third of our cohort had other head-
aches in addition to CM, all carefully phenotyped by
headache specialists and all recorded in separate head-
ache diaries to allow outcomes to be differentiated. It is
often speculated that those with multiple chronic head-
aches may have a worse response to treatments than
those with a single phenotype, however, there is no
published data supporting this. Occipital nerve stimula-
tion has been employed to treat a number of primary
headache conditions and it may be that the above view
does not apply to this particular treatment modality as
a single implant can potentially improve multiple con-
ditions. Although numbers were small, we did compare
outcomes between those with and without multiple
headache types at each time point. Interestingly, the
only time point at which there was a significant differ-
ence between the responses was at the point of final
follow-up where those with multiple phenotypes ap-
peared to have a significantly better response than
those with CM alone (30 % response rate of 66.7 vs
34.3 %; p = 0.012). The reason for this discrepancy is
unclear but likely due to a combination of numbers in
the two groups being too small to either show a real
difference at individual time points or a confounding
factor of a wide range of follow-up times being in-
cluded in the primary outcome measure of final follow-
up point. On further examination, the distribution of
final follow-up times is not normalized and this may in-
fluence the result at this point. This point obviously
needs clarification with data being collected from larger
cohorts but also with a well-controlled study comparing
those with multiple phenotypes to those with the same
phenotypes in isolation. Our current data does not sup-
port the concept that those with multiple headache
types respond poorly to ONS and thus such patients
should not be deprived of the treatment. In fact, ONS
is a good example of one procedure able to treat mul-
tiple conditions.
Assessments of headache related disability and quality
of life showed numerical improvements but only HIT-6
and EQ-VAS showed any statistical improvement in the
cohort as a whole. In a subgroup analysis, however,
those with a positive response were found to have statis-
tically significant reductions in a variety of quality of life
and affect measures which were not mirrored in the
non-responder group. A failure to observe significant
change across all assessments despite improvements in
headache frequency is reported in cases of epilepsy sur-
gery and spinal cord stimulation and has been attributed
to a “burden of normality” [1, 20]. Given that 33.9 % also
suffered other headache types that did not necessarily
respond completely to ONS and that nearly all patients
continued to have migraine pain of some level, they will
still exhibit a disability burden from their pain, even if
their migraine has significantly improved. This theory is
supported by a lower reduction in disability scores in the
multiple phenotype group compared to the CM alone
group of patients. Recently, Clark et al. reported on the
long term functional outcomes of combined supra-
orbital and occipital nerve stimulators for CM [9]. The
group found that improvements in functional outcome
(MIDAS and BDI) were only significant during the first
6-months post implant but not after prolonged follow-
up (average 44.5 months). They speculated that this was
due to the loss of a “honeymoon period” and as yet un-
explained complex interactions between pain and func-
tional status. Our cohort seems to suggest that this is
not necessarily accurate as even after a follow-up period of
nearly 4 years, over a third of patients still reported clinical
response and significantly reduced headache disability.
The strengths of this study include the large sample
size, the long follow up period and, importantly, the pro-
spective nature of the data collection (a first in long-
term observational ONS cohorts of CM). The real-life
nature of the data is also valuable. Patients were not
subjected to the strict inclusion criteria of a study and
represent the types of highly complex CM patient typic-
ally seen in specialized neuromodulation centers. The
limitations of this study are mainly centered on the lack
of a placebo or sham-stimulation group. However, it is
most unlikely that our observations can be explained by
placebo alone. We found that there was a delay of
months to reporting clinical effect (5.50 months) and a
delay before pain worsened when the device was off
(2.50 months). These observations are reproducible
across multiple ONS cohorts for a variety of primary
headache disorders and argue against a pure placebo ef-
fect [6, 16, 19]. This time delay may also explain why
shorter trials, reporting at 3-months post-implant, do
not mirror the more favorable open-label clinical experi-
ence of ONS in CM. Other factors against a pure pla-
cebo response include the previous intractable nature of
the group, a stable response with long-term follow up
and the previously quoted placebo rates of between 6
and 13 % in the controlled trials of ONS in CM being
below the 45.3 % response rate we quote here [30, 34].
The extrapolation of 2-weeks diary data to represent a
month is not ideal but the time-span was chosen as it is
the normal diary kept by all of our patients seen in
clinic, with or without ONS. The data was collected
from patients in a real clinical environment and we are
aware that asking for too much information may lead to
patients being unable to comply with requirements.
Therefore, a 2-week diary was chosen to ensure high
rates of compliance and diary completion. This method
may be more at risk of being influenced by natural fluc-
tuations in CM severity, however, in our cohort of highly
refractory patients such fluctuations were not commonly
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seen prior to ONS. In the future, consensus on the most
relevant outcome-measures for ONS and the develop-
ment of electronic-diaries may improve ease of dairy
keeping and allow long periods of data to be collected
easily.
The high levels of complications requiring surgical
intervention published in the literature have led to con-
cerns over the cost-effectiveness as well as safety of the
procedure. The current equipment used for ONS is de-
signed for spinal cord stimulation and not intended for
implantation in the occipital region. Advances in tech-
nology have already led to reductions in intervention
rates, for example a reduction in need for battery re-
placement with rechargeable IPG development, and
hopefully ONS specific equipment may be available in
the future. However, it must be noted that the one com-
pany (St Jude Medical) who were granted a European
CE Mark Approval for the use of their ONS to treat CM
in 2012 had that approval removed in 2014 as it was felt
that there was not enough data to demonstrate that the
benefits outweighed the risk of therapy [35]. These con-
cerns are a major issue in neuromodulation for migraine
and raise the need for high quality, well planned, large
placebo-controlled trials to look at efficacy and safety in
the long-term treatment of CM.
Conclusion
In this uncontrolled, open-label prospective observa-
tional study with long-term follow-up of efficacy, func-
tional outcome and safety of ONS in highly intractable
complex CM patients, over 40 % of patients reported
sustained clinical benefit after a mean follow-up of
4 years. Sustained benefit was seen even in those with
multiple headache types in addition to CM. Responders
showed improvements in functional outcomes and head-
ache related disability. Adverse event rates are low when
implants are conducted in specialist centers. There ap-
pears to be a time delay of up to 6 months before clin-
ical effect of ONS is seen which calls into question the
practice of trial stimulation prior to implant. There are
still concerns over the risk to benefit ratio and cost ef-
fectiveness of ONS despite positive open-label data and
a well-designed double-blind controlled trial with long-
term follow-up is needed to clarify the position of neu-
romodulation in chronic migraine.
Additional file
Additional file 1: Figure S1. Examples of headache diaries used
throughout the study. Example of headache diaries in a patient with
both chronic migraine and chronic cluster headache. The patient has
been asked to record her migraine pain severity on VRS scale 0–10 at
every hour during the day. Note that on first diary, patient has recorded 2
cluster attacks at around 0750 and 1900. These are replicated on her
separate cluster attack diary shown in Figure S1b. The use of separate
headache diaries for each phenotype allowed patient and investigators
to ascertain outcome for each phenotype. a: Example of chronic
migraine diary. b: Example of cluster attack diary. (DOCX 128 kb)
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